Formulation Features

Designed for Ocular Comfort3
  • No blurred vision reported in clinical studies3
  • pH of 6.5, close to human tears3
  • Comfortable upon instillation3,4
No Shaking Required to Resuspend Drug1
  • Dose uniformity–consistent concentration in every drop, every time5
  • Improved TID dosing1,2
    • Less frequent than LOTEMAX® GEL
Lowest Preservative in a Loteprednol Etabonate Formulation1,2,6-10
  • 0.003% BAK, same as LOTEMAX® GEL1,2,6
    • 70% less than LOTEMAX® Suspension (loteprednol etabonate ophthalmic gel) 0.50%
Formulated With Moisturizing Ingredients11
  • Glycerin11
  • Propylene glycol11

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

  • LOTEMAX® SM, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If LOTEMAX® SM is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation.
  • The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
  • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections.
  • Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
  • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.
  • Contact lenses should not be worn when the eyes are inflamed.
  • There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Click here for full Prescribing Information for LOTEMAX® SM.

References: 1. LOTEMAX SM [prescribing information]. Bridgewater, NJ: Bausch & Lomb, Inc. 2. LOTEMAX GEL [prescribing information]. Bridgewater, NJ: Bausch & 3. Fong R, Silverstein BE, Peace JH, Williams JI, Vittitow JL. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery. J Cataract Refract Surg. 2018;44(10):1220-1229. 4. Data on file. Bausch & Lomb, Inc. 5. Marlowe ZT, Davio SR. Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%). Clin Ophthalmol. 2014;8:23-29. 6. LOTEMAX ophthalmic suspension [prescribing information]. Bridgewater, NJ: Bausch & Lomb, Inc. 7. LOTEMAX OINTMENT [prescribing information]. Bridgewater, NJ: Bausch & Lomb, Inc. 8. Alrex [prescribing information]. Bridgewater, NJ: Bausch & Lomb, Inc. 9. Zylet [prescribing information]. Bridgewater, NJ: Bausch & Lomb, Inc. 10. Inveltys [prescribing information]. Waltham, MA. Kala Pharmaceuticals, Inc. 11. Coffey MJ, DeCory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol. 2013;7:299-312.